Results 341 to 350 of about 785,489 (353)

Feedback regulation of EGFR signalling: decision making by early and delayed loops

Nature Reviews Molecular Cell Biology, 2011

exaly  

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Nature Reviews Cancer, 2010
William Pao
exaly  

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Cancer Cell, 2010
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom   +2 more
exaly  

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Nature Reviews Clinical Oncology, 2010
Deric L Wheeler, Paul M Harari
exaly  

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Nature Reviews Clinical Oncology, 2018
Gonzalo Recondo, Benjamin Besse, Luc Friboulet   +2 more
exaly  

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

Nature, 2011
Weiwei Yang, , Zhimin Lu
exaly  

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Nature Reviews Clinical Oncology, 2009
Nicola Normanno, Floriana Morgillo, Antonella De Luca   +2 more
exaly  

Afatinib—new therapy option for EGFR-mutant lung cancer

Nature Reviews Clinical Oncology, 2013
Helena A Yu, William Pao
exaly  

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Nature Medicine, 2018
Khyati Shah, Ashley Maynard, Jonathan Kuhn   +2 more
exaly  

Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma

Ca-A Cancer Journal for Clinicians, 2018
exaly